0001766400-25-000139
SEC filingRevenue grew 26.8% YoY to $229M, driven by acquisitions and organic gains, but operating margin contracted 160 bps to 4.4%.
Total revenue for the three months ended September 30, 2025 increased 26.8% to $229.0M, driven by strong organic growth and acquisitions. Home health and hospice services revenue grew 27.9% to $173.6M, while senior living services revenue increased 23.2% to $55.5M. However, cost of services grew 28.4% to $185.4M (81.0% of revenue vs 80.0% prior year), and general and administrative expenses surged 48.2% to $19.3M (8.4% of revenue vs 7.2%). Operating income declined 5.2% to $10.2M, resulting in an operating margin of 4.4%, down 160 bps from 6.0%. Net income attributable to Pennant decreased slightly to $6.1M from $6.2M, though non-GAAP Adjusted EBITDA rose 14.5% to $17.3M.
Home Health and Hospice Services: Revenue increased $37.9M YoY, driven by a 36.2% rise in total home health admissions and a 17.4% higher average daily hospice census. Acquisitions contributed $25.3M of the growth. Cost of services as a percentage of revenue rose 50 bps to 83.5%, reflecting wage pressures and acquisition integration. Segment Adjusted EBITDAR from Operations was $29.1M, up from $23.7M.
Senior Living Services: Revenue grew $10.5M YoY, with occupancy improving 180 bps to 80.9% and average monthly revenue per occupied unit increasing 7.4% to $5,195. Acquisitions added $6.6M. Cost of services as a percentage of revenue increased 220 bps to 73.0%, primarily due to reduced state relief funding. Segment Adjusted EBITDAR from Operations rose to $15.3M from $13.4M.
Management did not provide explicit guidance, but the MD&A highlights several trends and risks. The company expects continued acquisition activity, with 19 home health/hospice agencies and 4 senior living communities added year-to-date. Regulatory developments include a proposed -6.4% net payment update for home health (CY 2026) and a +2.6% final rule for hospice (FY 2026), along with potential impacts from the One Big Beautiful Bill Act on Medicaid. The company believes existing cash, operating cash flow, and the $250M revolving credit facility (with $219.8M available as of Sep 30, 2025) are sufficient for near-term liquidity. A subsequent $100M term loan was added on Nov 3, 2025 to refinance revolving debt. Key focus areas remain organic growth through admissions and occupancy improvements, margin management in a competitive labor environment, and disciplined acquisition integration.
Operating cash flow (CFO) of $27.3M for the nine months ended September 30, 2025, comfortably supports the company's capital needs, though investing activities consumed $75.0M, primarily due to business acquisitions. CFO grew 46% year-over-year, outpacing the increase in net income, indicating improved working capital management. The cash conversion cycle appears favorable, with changes in operating assets and liabilities contributing $1.8M. Capital expenditures are not separately disclosed but are embedded in investing outflows. The company did not report share repurchases or dividends. Financing activities provided $25.7M, mostly from debt drawdowns, but net cash decreased by $21.9M due to heavy investment. The end-period cash balance of $2.3M remains low relative to operating scale, but the company has access to a credit facility. Overall, cash generation is strong, but aggressive acquisition spending may strain liquidity if not moderated.